Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 50 publications.

Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik K. Evaluation of physician knowledge of safety and safe use information for intravitreal aflibercept injection in Europe: a second survey of physicians following dissemination of updated risk-minimization materials. Pharmaceut Med. 2024 Jan;38(1):63-73. doi: 10.1007/s40290-023-00506-7

Ho KA, Pierce A, Stoltenberg M, Tarancon T, Mansfield C. Eliciting exploratory patient preference data: a case study in a rare disease. Pharmaceut Med. 2024 Jan;38(1):55-62. doi: 10.1007/s40290-023-00509-4.

Wesselink AK, Lovett SM, Weinberg J, Geller RJ, Wang TR, Regan AK, Willis MD, Perkins RB, Yland JJ, Koenig MR, Rothman KJ, Hatch EE, Wise LA. COVID-19 vaccination and menstrual cycle characteristics: a prospective cohort study. Vaccine. 2023 Jun 29;41(29):4327-34. doi: 10.1016/j.vaccine.2023.06.012

Talbird SE, Anderson SA, Nossov M, Beattie N, Rak AT, Diaz-Mitoma F. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis b in adults in the United States. Vaccine. 2023 May 26;41(23):3506-17. doi: 10.1016/j.vaccine.2023.04.022

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036

Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002

Carrico J, Talbird SE, La EM, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine. 2021 Aug 23;39(36):5187-97. doi: 10.1016/j.vaccine.2021.07.029

La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021 May 6;39(19):2660-7. doi: 10.1016/j.vaccine.2021.03.071

Guzman-Holst A, Luna-Casas G, Cervantes-Apolinar MY, Huerta-Garcia GC, Juliao P, Sanchez-Gonzalez G. Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: an ecological database study with time-series analysis. Vaccine. 2021 Apr 15;39(16):2311-8. doi: 10.1016/j.vaccine.2021.02.038

Juliao P, Abadia I, Welby S, Wery S, Wong D, De Leon T, DeAntonio R, Naranjo L, Guignard A, Marano C. Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine. 2021 Jan 3;39(1):26-34. doi: 10.1016/j.vaccine.2020.11.030

Carrasquilla G, Porras A, Martinez S, DeAntonio R, Devadiga R, Caceres DC, Juliao P. Incidence and mortality of pertussis disease in infants <12 months of age following introduction of pertussis maternal universal mass vaccination in Bogotá, Colombia. Vaccine. 2020 Oct 27;38(46):7384-92. doi: 10.1016/j.vaccine.2020.07.046

Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O’Neil C, Weber DJ, Butler AM. Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Vaccine. 2020 Jun 6;38(33):5178-86. doi: 10.1016/j.vaccine.2020.06.020

Orta OR, Hatch EE, Regan AK, Perkins R, Wesselink AK, Willis SK, Mikkelsen EM, Rothman KJ, Wise LA. A prospective study of influenza vaccination and time to pregnancy. Vaccine. 2020 Jun 2;38(27):4246-51. doi: 10.1016/j.vaccine.2020.04.054

Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C. The adult vaccination landscape in the United States during the Affordable Care Act era: results from a large retrospective database analysis. Vaccine. 2020 Mar;38(14):2984-94. doi: 10.1016/j.vaccine.2020.02.057

Baker MA, Jankosky C, Yih WK, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, DeLuccia S, Lin ND, McMahill-Walraven CN, Menschik D, Selvan MS, Selvam N, Chen Tilney R, Zichittella L, Lee GM, Kawai AT. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. Vaccine. 2020 Feb 24;38(9):2166-71. doi: 10.1016/j.vaccine.2020.01.046

Guzman-Holst A, DeAntonio R, Prado-Cohrs D, Juliao P. Barriers to vaccination in Latin America: a systematic literature review. Vaccine. 2020 Jan 16;38(3):470-81. doi: 10.1016/j.vaccine.2019.10.088

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Kawai AT, Martin D, Henrickson SE, Goff A, Reidy M, Santiago D, Selvan N, McMahill-Walraven C, Lee GM. Validation of febrile seizures identified in the Sentinel Post-Licensure Rapid Immunization Safety Monitoring Program. Vaccine. 2019 Jul 9;37(30):4172-6. doi: 10.1016/j.vaccine.2019.05.042.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):219-33. doi: 10.1007/s40290-019-00279-y

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport E, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Evaluation of physician knowledge of the key safety information for aflibercept in Canada: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):235-46. doi: 10.1007/s40290-019-00278-z

Layton JB, Butler AM, Brookhart MA, Panozzo CA. Variation in rotavirus vaccination coding in state US medicaid data. Vaccine. 2019 May 16;37(22):2892-5. doi: 10.1016/j.vaccine.2019.02.074

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: a cohort study of US claims database. Vaccine. 2019 Feb 21;37(9):1235-44. doi: 10.1016/j.vaccine.2018.11.079

Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson B, Levin M. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018 Oct 29;36(45):6810-8. doi: 10.1016/j.vaccine.2018.08.080

Groom HC, Irving SA, Koppolu P, Smith N, Vazquez-Benitez G, Kharbanda EO, Daley MF, Donahue JG, Getahun D, Jackson LA, Tse Kawai A, Klein NP, McCarthy NL, Nordin JD, Sukumaran L, Naleway AL. Uptake and safety of Hepatitis B vaccination during pregnancy: a vaccine safety datalink study. Vaccine. 2018 Oct 1;36(41):6111-6. doi: 10.1016/j.vaccine.2018.08.074

McGrath LJ, Layton JB, Krueger WS, Kshirsagar AV, Butler AM. High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013. Vaccine. 2018 Oct 1;36(41):6087-94. doi: 10.1016/j.vaccine.2018.08.079

Poulos C, Standaert B, Sloesen B, Stryjewska I, Janitsary A, Hauber B. Preferences for vaccines against children's diarrheal illness among mothers in Poland and Hungary. Vaccine. 2018 Sep 25;36(40):6022-9. doi: 10.1016/j.vaccine.2018.08.001

Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005

Poulos C, Curran D, Anastassopoulou A, De Moerlooze L. German travelers' preferences for travel vaccines assessed by a discrete choice experiment. Vaccine. 2018 Feb 8;36(7):969-78.

Rouse CE, Eckert LO, Babarinsa I, Fay E, Gupta M, Harrison MS, Kawai AT, Kharbanda EO, Kucuku M, Meller L, Mallett Moore T, Subelj M, Kochhar S, Tavares-Da-Silva F, GAIA Abortion Work Group, Brighton Collaboration Abortion Working Group. Spontaneous abortion and ectopic pregnancy: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data - Commentary. Vaccine. 2017 Dec 4;35(48 Pt A):6563-74. doi: 10.1016/j.vaccine.2017.01.047

Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9

Layton JB, Butler AM, Li D, Boggess KA, Weber DJ, McGrath LJ, Becker-Dreps S. Prenatal Tdap immunization and risk of maternal and newborn adverse events. Vaccine. 2017 Jul 24;35(33):4072-8. doi: 10.1016/j.vaccine.2017.06.071

DaSilva T, Gonik B, Mcmillan M, Keech C, Dellicour S, Bhange S, Tila M, Harper DM, Woods C, Kawai AT, Kochhar S, Munoz FM, Brighton Collaboration Stillbirth Working Group. Stillbirth: case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2016 Dec 1;34(49):6057-68. doi: 10.1016/j.vaccine.2016.03.044

DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H, Macartney KK, Joshi J, Oneko M, Rose AE, Dolk H, Trotta F, Spiegel H, Tomczyk S, Shrestha A, Kochhar S, Kharbanda EO, Brighton Collaboration Congenital Anomalies Working Group. Congenital anomalies: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016 Dec 1;34(49):6015-26. doi: 10.1016/j.vaccine.2016.03.047

Kurosky SK, Davis KL, Krishnarajah G. Completion and compliance of childhood vaccinations in the United States. Vaccine. 2016 Jan 12;34(3):387-94. doi: 10.1016/j.vaccine.2015.11.011

Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B. Treatment patterns, costs, and survival among Medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015 Jun 15;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87

Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness. Vaccine. 2015 Mar 10;33(11):1313-6. doi: 10.1016/j.vaccine.2015.01.069

Thyagarajan (Hoffman) V, Su S, Gee J, Duffy J, McCarthy NL, Chan KA, Weintraub ES, Lin ND. Identification of seizures among adults and children following influenza vaccination using health insurance claims data. Vaccine. 2013 Dec 5;31(50):5997-6002. doi: 10.1016/j.vaccine.2013.10.026

McCarthy NL, Gee J, Lin ND, Thyagarajan (Hoffman) V, Pan Y, Su S, Turnbull B, Chan KA, Weintraub E. Evaluating the safety of influenza vaccine using a claims-based health system. Vaccine. 2013 Dec 5;31(50):5975-82.

Karve S, Meier G, Davis KL, Misurski DA, Wang CC. Influenza-related health care utilization and productivity losses during seasons with and without a match between the seasonal and vaccine virus B lineage. Vaccine. 2013;31(33):3370-88.

Tse (Kawai) A, Tseng HF, Greene SK, Vellozzi C, Lee GM, VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012 Mar 2;30(11):2024-31. doi: 10.1016/j.vaccine.2012.01.027

Talbird S, Knerer G, Hausdorff W, Taylor T, Frostad CR. Reply to Strutton et al.: response to “Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries”. Vaccine. 2011 Oct 1;29(44):7591-2.

Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine. 2010 Nov 19;28(Suppl 6):G14-22.

Talbird SE, Taylor TN, Knoll S, Frostad CR, Marti SG. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010 Nov 19;28(Suppl 6):G23-9.

Talbird SE, Ismaila AS, Taylor TN. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine. 2010 Nov 19;28(Suppl 6):G3-G13.

Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010 Nov 19;28(Suppl 6):G30-8.

Brown DS, Johnson FR, Poulos C, Messonnier ML. Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010 Feb 1;28(7):1702-8.

Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine. 2009 Mar 4;27(10):1609-21.

Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, Anh DD, Agtini M, Bhuttai Z, DOMI Typhoid Economics Study Group . The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008 Nov 25;26(50):6305-16.

Doward LC, McKenna SP, Meads DM, Jovell AJ, Fisk J, Eckert BJ. The international development of patient reported outcome indices for multiple sclerosis. Poster presented at the 2006 Sixteenth Meeting of the European Neurological Society; May 2006. Lausanne, Switzerland. [abstract] J Neurol. 2006; 253(Suppl 2):125.